NextCure joins the B7-H4 brigade
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
KAT6 catalysts to kick off 2025
Olema will soon enter the clinic, and Pfizer could shortly be in phase 3.
A second-line degrader battle beckons
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
ASCO 2024 movers – Affimed wins, Caribou loses
As the dust settles on ASCO the weekend’s immediate winners and losers emerge.
ESMO Breast Cancer 2024 – Olema digs deep to declare victory
Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.
The month ahead: May’s remaining events
ASCO is fast approaching, but in the meantime Olema will have an important readout.
